Crc Folfoxiri

Mauricio Lema Medina MD www.mauriciolema.com CRC

NOMBRE PACIENTE (IDENTIFICACIÓN) Esquema: FOLFOXIRI Descripción Folinato, fluoruracilo infusional, Irinotecán y oxaliplatino Referencia Falcone, A. et al. J Clin Oncol 2007 25: 1670-1676 Indicación Cáncer colon y recto Presentaciones Medicamento Presentación Folinato de calcio Amp Fluoruracilo Amp Irinotecán Amp Oxaliplatino Amp Talla (cm) Peso (kg) Superficie corporal (m2) Intensidad de dosis (%) Cálculo de dosis Medicamento Folinato de calcio Fluoruracilo Irinotecán Oxaliplatino

mg/m2 200 3200 165 85

Cantidad 50 500 100 50

Unidades mg mg mg mg

160 56 1.58 100

Entrar la talla Entrar el peso El programa calcula la superficie corporal Entrar la intensidad de dosis

Dosis 100% 315 5047 260 134

Dosis Calculada

315 5047 260 134

No. Ampollas 6.31 10.09 2.60 2.68

Cantidad 50 500 100 50 4 8

Unidades mg mg mg mg mg mg

Número 14 22 6 6 10 2

Solicitud de Medicamentos Medicamento Presentación Folinato de calcio Amp Fluoruracilo Amp Irinotecán Amp Oxaliplatino Amp Dexametasona Amp Ondansetrón Amp

Protocolo de administración en la página 2

Amp/inf

Amp/ciclo

7 11 3 3

14 22 6 6

Mauricio Lema Medina MD www.mauriciolema.com CRC

Página 2 Protocolo de Administración Premedicación Ondansetron Dexametasona Posteriormente Irinotecán Oxaliplatino Folinato de calcio Fluoruracilo

Dosis 8 20

Unidades mg mg

260 134 315 5047

mg mg mg mg

Descripción IV antes de quimioterapia día 1 y 2 IV antes de quimioterapia día 1 y 2 en D5% 500 IV en 60 minutos, día 1 en D5% 500 IV en 120 minutos, día 1 IV en SSN 250 cc, infusión de 120 minutos, día 1 En infusión intravenosa continua de 48 horas, iniciando en el día 1

Repetir el anterior protocolo en el día 15 Bases: Irinotecán 165 mg/m2 en 60 minutos, Folinato 200 mg/m2 infusión 2 horas, Fluoruracilo 3200 mg/m2 en infusió 48 horas Oxaliplatino 85 mg/m2, en infusión de 2 horas, día 1; se repite cada 15 días BSA fórmula:

0,20274*POTENCIA(C13/100;0,725)*POTENCIA(C14;0,425)

Hoja Creada por: Mauricio Lema Medina MD

Falcone, Alfredo, Ricci, Sergio, Brunetti, Isa, Pfanner, Elisabetta, Allegrini, Giacomo, Barbara, Cecilia, Crino, Lucio, Benedetti, Giovanni, Evange

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluoro J Clin Oncol 2007 25: 1670-1676

From November 2001 to April 2005, we enrolled patients who met the following eligibility criteria: adenocarcinoma of the co

, Benedetti, Giovanni, Evangelista, Walter, Fanchini, Laura, Cortesi, Enrico, Picone, Vincenzo, Vitello, Stefano, Chiara, Silvana, Granetto, Cristina, Porcile, Gia

ared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo

adenocarcinoma of the colon or rectum, unresectable metastatic disease, age 18 to 75 years, Eastern Cooperative Oncology Group (EC

Granetto, Cristina, Porcile, Gianfranco, Fioretto, Luisa, Orlandini, Cinzia, Andreuccetti, Michele, Masi, Gianluca

rectal Cancer: The Gruppo Oncologico Nord Ovest

ative Oncology Group (ECOG) performance status of 2 or lower if age 70 years or younger or ECOG performance status of 0 if age 71

ance status of 0 if age 71 to 75 years, measurable disease according to WHO criteria, leukocyte count of at least 3,500/mm

ast 3,500/mm 3, neutrophils count of at least 1,500/mm 3, platelet count of at least 100,000/mm 3, serum creatinine of 1.3 mg/dL or less, se

ne of 1.3 mg/dL or less, serum bilirubin less than 1.5 mg/dL and AST, ALT, and alkaline phosphatase 2.5 x normal values or less ( 5 if li

rmal values or less ( 5 if liver metastases). Previous fluoropyrimidine-based adjuvant chemotherapy was allowed if ended more than 6 m

ed if ended more than 6 months before random assignment. Exclusion criteria were previous palliative chemotherapy for metastatic dise

herapy for metastatic disease; previous chemotherapy including irinotecan or oxaliplatin, symptomatic cardiac disease, myocardial

disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia, active infections, inflammatory bowel disease; and total

y bowel disease; and total colectomy. The study was conducted in accordance to Helsinki declaration and to Good Clinical Practice guid

Good Clinical Practice guidelines, and patients were informed of the investigational nature of the study and provided their written informe

vided their written informed consent before registration onto the study. The protocol was approved by the ethics committee of

cs committee of all participating institutions.